Bio-identical hormones and method of use

• US 6,967,194 B1
• Filed: 09/18/2002
• Issued: 11/22/2005
• Est. Priority Date: 09/18/2002
• Status: Expired due to Fees

• Current Assignee: Susan Matsuo
• Original Assignee: Susan Matsuo
• Inventors: Matsuo, Susan, Barr, Teresa Leigh
• Primary Examiner(s): Lilling, Herbert J.
• Application Number:
  US10/246,358
• Time in Patent Office: 1,161 Days
• Field of Search: 514/171, 514/172, 514/169, 514/505, 514/184, 424/655, 424/450
• US Class Current: 514/171
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/568 substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
• CPC Class Codes: Y10T 436/10 Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Abstract

The invention is a method for balancing and maintaining Cortisol levels in humans by identifying the hormonal needs for a human, using blood tests or saliva tests to ascertain the current relationship between the DHEA, androstenedione, testosterone and androstenediol for that human, inserting the low values of each hormone level into a hormone tree, balancing the DHEA with the androstenediol and the testosterone and the androstenediol in a ratio which is normal for the particular person, modifying the inserted values individually forming modified values wherein the modified values account for a selected symptoms, changing the modified value to accommodate for sex type of an individual forming a gender accommodated value, and creating a morning and evening dose that priors an amount of bio-identical hormones to bring the gender accommodated value up to the normal ratio.

Claims

1. A morning dose of bio-identical hormones in a solvent with a vasodilator, a hormone modulator, and a carrier, for balancing and maintaining Cortisol levels in a human comprising:

a. dehydroepiandrosterone 0.005–

41 wt %;

b. androstenedione 0.005–

41 wt %;

c. androdiol 0.005–

41 wt %;

d. ethyoxydiglycol 0.005–

41 wt %;

e. pentoxifylline 0.005–

10 wt %;

f. testosterone 0.125–

50 wt %;

g. meclofenoxate 0.005–

22 wt %; and

h. carrier q.s.

2. The morning dose of claim 1, wherein the carrier is selected from the group creams, lotions, sprays, gels, and enhanced oils.

3. The morning dose of claim 1, consisting of:

a. dihydroepiandrosterone 3.5 wt %;

b. androstenedione 4.89 wt %;

c. androdiol 4.89 wt %;

d. ethyoxydiglycol 8.89 wt %;

e. pentoxyfilline 4.44 wt %;

f. testosterone 0.011 wt %;

g. meclofenoxate 1.77 wt %; and

h. carrier.q.s.

4. The morning dose of claim 1 for post menopausal women further comprising estriol 0.005–

10 wt % and estridiol 001–

20 wt %%, wherein estriol is present at least 5 times greater than the estrodiol.

5. The morning dose of claim 4, consisting of estriol 0.32 wt % and estriodiol 0.08 wt %.

6. The morning dose of claim 1, further comprising 0.005–

41 wt % pregnenolone wherein the dose is modified based on the presence of physiological symptoms including infertility, hair loss, weight gain, depression, anxiety, panic attacks, insomnia, prostate issues, sexual enjoyment problems, irregular menstrual cycles and libido.

7. The morning dose of claim 1 for potentially procreating women comprising between estriol 0.005–

10 wt %, estrone 0.001–

10 wt % and estridiol 0.001–

10 wt %.

8. The morning dose of claim 1 for potentially procreating women further comprising estriol 0.325 wt %, estridiol 0.04 and estrone 0.04 wt %.

9. A dose for maintaining sex hormone levels for transsexuals having a low testosterone value comprising:

a. dehydroepiandrosterone 0.005 to 41 wt %;

b. androstenedione 0.005 to 41 wt %;

c. androdiol 0.005 to 41 wt %;

d. ethoxy diglycol 0.005 to 41 wt %;

e. pentoxifylline 0.005 to 10 wt %;

f. testosterone 0.125 to 50 wt %;

g. meclofenoxate 0.005 to 22 wt %; and

a. a carrier q.s.